Topics

  • Education and Research

November 16, 2026

A research group led by Professor of the Faculty of School of Medicine and Associate Professor Saegusa of the Faculty of Faculty of Pharmaceutical Sciences has identified a plasma metabolic biomarker that predicts the efficacy of afatinib treatment for lung cancer.

A research group led by Professor Yoshihiko Seki and Senior Assistant Professor Ken Honda of the Department Internal Medicine, Teikyo University School of Medicine, and Associate Professor Daisuke Saegusa and Senior Assistant Professor Tomoko Fukuchi of the Clinical Analysis Laboratory, Faculty of Faculty of Pharmaceutical Sciences, in collaboration with 21 institutions nationwide, has identified a new plasma metabolite biomarker that can predict the therapeutic effect and survival period of afatinib in EGFR gene mutation-positive non-small cell lung cancer patients before treatment.

In this study, we comprehensively analyzed 630 metabolites from the plasma of 101 patients and extracellular vesicles (EVs) of 99 patients. As a result, we found that histidine and five lysophosphatidylcholines (LPCs) in plasma were promising predictors of progression-free survival (PFS), while four amino acids containing histidine, PC ae C30:1, and a specific ceramide (a negative predictor of shortened survival) were promising predictors of overall survival (OS). On the other hand, no significant correlation with survival was found from metabolites derived from EVs, suggesting that plasma metabolites specifically and sensitively reflect the host's systemic metabolic and immune state.
Furthermore, we demonstrated that a "prognosis score" combining these blood metabolites (a total of 11 types, excluding duplicates) can significantly classify patients into three groups with different survival times (good, intermediate, and poor) before treatment. Amidst the increasing prevalence of combination therapies with high toxicity and treatment costs, this score is expected to contribute to the realization of personalized medicine (precision medicine) by identifying in advance patients (approximately one-third of the total) who can expect sufficient long-term survival with afatinib monotherapy, thereby avoiding unnecessary treatments.

These results were published online on November 3, 2026 (Tuesday) in the international academic journal "Therapeutic Advances in Medical Oncology".

To the topic List